BeStock  
Stocks › Biotechnology › CLYM

Climb Bio CLYM

US equityMarket cap rank #3548Biotechnology
$9.19 −$0.09 (-0.97%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $9.03 -1.76%
Open$8.98
Prev close$9.28
Day range$8.90 – $9.40
Volume770.2K
Market cap$539.80M
P/E (TTM)–
Dividend yield–

Fundamentals

Latest reported quarter: Q3, ended Sep 2026

Revenue$0.00
Operating profit-$16.89M-13.4% YoY
Net profit-$14.57M-13.1% YoY
Diluted EPS-$0.18+5.3% YoY
Free cash flow-$12.82M-4.7% YoY
Operating cash flow-$12.00M

Revenue, last 8 quarters

$0.0Dec '24$0.0Mar '25$0.0Jun '25$0.0Sep '25$0.0Dec '25$0.0Mar '26$0.0Jun '26$0.0Sep '26

Net profit, last 8 quarters

$-8.4MDec '24$-20.8MMar '25$-8.7MJun '25$-12.9MSep '25$-17.5MDec '25$-13.7MMar '26$-13.5MJun '26$-14.6MSep '26

Diluted EPS by quarter

-0.13Dec '24-0.31Mar '25-0.13Jun '25-0.19Sep '25-0.26Dec '25-0.20Mar '26-0.18Jun '26-0.18Sep '26

Free cash flow by quarter

$-5.5MDec '24$-15.4MMar '25$-11.2MJun '25$-12.2MSep '25$-15.6MDec '25$-14.4MMar '26$-10.8MJun '26$-12.8MSep '26

Annual revenue

$0.0FY20$0.0FY21$0.0FY22$0.0FY23$0.0FY24$0.0FY25

Profitability & balance sheet

Return on equity-29.3%
Return on assets-28.3%
Return on invested capital-32.9%
Current ratio26.58
Liabilities / assets3.6%
Cash & investments$205.42M
Total debt$605,000.00
Net cash (debt)$204.82M

Income statement

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Operating Revenue $0.00 $0.00 $0.00 $0.00 $0.00
Operating Expense $16.89M $15.36M $15.21M $67.88M $19.30M
Selling and Admin Expenses $5.85M $5.65M $5.84M $21.17M $5.56M
-General & Admin Expense $5.85M $5.65M $5.84M $21.17M $5.56M
Research & Development $11.04M $9.71M $9.37M $46.71M $13.74M
Operating Profit -$16.89M -$15.36M -$15.21M -$67.88M -$19.30M
Net Non-Operating Interest Income (Expense) $2.33M $1.86M $1.51M $8.32M $1.83M
Non-Operating Interest Income $2.33M $1.86M $1.51M $8.32M $1.83M
Other Income (Expense) -$5,000.00 $6,000.00 -$25,000.00 -$291,000.00 -$46,000.00
Gain on Sale of Security -$5,000.00 $6,000.00 -$25,000.00 -$291,000.00 -$46,000.00
Pretax Profit -$14.57M -$13.50M -$13.72M -$59.85M -$17.52M
Net Profit -$14.57M -$13.50M -$13.72M -$59.85M -$17.52M
Profit from Continuing Operations -$14.57M -$13.50M -$13.72M -$59.85M -$17.52M
Net Income to Parent Company -$14.57M -$13.50M -$13.72M -$59.85M -$17.52M
Net Income to Common Stockholders -$14.57M -$13.50M -$13.72M -$59.85M -$17.52M
Basic EPS -$0.18 -$0.18 -$0.20 -$0.88 -$0.26
Diluted EPS -$0.18 -$0.18 -$0.20 -$0.88 -$0.26
Special Income (Charges) – – – $0.00 $0.00

Balance sheet

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Assets $236.56M $246.29M $152.37M $167.74M $167.74M
Total Current Assets $210.15M $186.64M $113.40M $105.85M $105.85M
Cash and Cash Equivalents & Short-Term Investments $205.42M $183.12M $109.56M $101.08M $101.08M
-Cash and Cash Equivalents $39.73M $44.11M $8.36M $35.69M $35.69M
-Short Term Investments $165.69M $139.02M $101.21M $65.40M $65.40M
Other Current Assets $4.73M $3.51M $3.84M $4.77M $4.77M
Total Non-Current Assets $26.42M $59.66M $38.97M $61.90M $61.90M
Net PPE $2.32M $1.91M $697,000.00 $793,000.00 $793,000.00
-Gross PPE $2.32M $1.91M $697,000.00 $793,000.00 $793,000.00
Investments and Advances $22.20M $56.10M $36.74M $59.57M $59.57M
-Available for Sale Securities $22.20M $56.10M $36.74M $59.57M $59.57M
Other Non-Current Assets $1.89M $1.65M $1.53M $1.53M $1.53M
Total Liabilities $8.51M $6.75M $4.29M $7.27M $7.27M
Total Current Liabilities $7.91M $5.93M $4.07M $6.98M $6.98M
Payables $1.06M $1.13M $860,000.00 $2.27M $2.27M
-Accounts Payable $1.06M $1.13M $860,000.00 $2.27M $2.27M
Current Accrued Expenses $6.39M $4.30M $2.95M $4.46M $4.46M
Short-Term Debt and Capital Lease Obligation $463,000.00 $501,000.00 $263,000.00 $256,000.00 $256,000.00
-Current Capital Lease Obligation $463,000.00 $501,000.00 $263,000.00 $256,000.00 $256,000.00
Total Non-Current Liabilities $605,000.00 $813,000.00 $216,000.00 $285,000.00 $285,000.00
Long Term Debt and Capital Lease Obligation $605,000.00 $813,000.00 $216,000.00 $285,000.00 $285,000.00
-Long Term Capital Lease Obligation $605,000.00 $813,000.00 $216,000.00 $285,000.00 $285,000.00
Total Equity $228.05M $239.55M $148.09M $160.48M $160.48M
Stockholders' Equity $228.05M $239.55M $148.09M $160.48M $160.48M
Capital Stock $6,000.00 $6,000.00 $5,000.00 $5,000.00 $5,000.00
-Common Stock $6,000.00 $6,000.00 $5,000.00 $5,000.00 $5,000.00
Additional Paid-In Capital $560.10M $556.56M $451.37M $449.76M $449.76M
Retained Earnings -$331.52M -$316.95M -$303.45M -$289.73M -$289.73M
Gains/Losses Not Affecting Retained Earnings -$528,000.00 -$67,000.00 $157,000.00 $435,000.00 $435,000.00
Prepaid Assets – $3.51M $3.84M $4.77M $4.77M
Other Current Liabilities – $295,000.00 $113,000.00 $59,000.00 $59,000.00

Cash flow

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Operating Cash Flow -$12.00M -$10.55M -$14.38M -$54.36M -$15.64M
Net cash flow from continuing operations -$12.00M -$10.55M -$14.38M -$54.36M -$15.64M
Net Income from Continuing Operations -$14.57M -$13.50M -$13.72M -$59.85M -$17.52M
Gain/Loss from Continuing Operations $2,000.00 -$16,000.00 $21,000.00 $18,000.00 -$5,000.00
Depreciation & Depletion & Amortization $195,000.00 $33,000.00 $38,000.00 $97,000.00 $30,000.00
Other Non-Cash Items $222,000.00 -$1,000.00 $58,000.00 $201,000.00 $57,000.00
Change in Working Capital $579,000.00 $1.84M -$2.07M -$601,000.00 $1.27M
-Change in Prepaid Assets -$648,000.00 $327,000.00 $929,000.00 -$816,000.00 -$706,000.00
-Change in Payables and Accrued Expense $2.00M $1.14M -$2.94M $1.94M $2.01M
-Change in Other Current Assets -$523,000.00 $304,000.00 $0.00 -$1.51M $0.00
-Change in Other Current Liabilities -$246,000.00 $67,000.00 -$62,000.00 -$207,000.00 -$39,000.00
Net cash flow from investing $6.40M -$57.26M -$12.96M $2.83M $25.54M
Net Cash Flow from Continuing Investing Activities $6.40M -$57.26M -$12.96M $2.83M $25.54M
Net PPE Purchase and Sale -$820,000.00 – – -$186,000.00 $0.00
Net Investment Purchase and Sale $7.22M -$57.00M -$12.96M $3.02M $25.54M
Financing Cash Flow $1.22M $103.70M $5,000.00 -$21,000.00 -$21,000.00
Net Cash Flow from Continuing Financing Activities $1.22M $103.70M $5,000.00 -$21,000.00 -$21,000.00
Net Common Stock Issuance $0.00 – – $0.00 $0.00
Proceeds from Stock Option Exercised $1.50M $335,000.00 $5,000.00 $65,000.00 $65,000.00
Ending Cash Balance $39.87M $44.25M $8.36M $35.69M $35.69M
Net Change in Cash -$4.38M $35.89M -$27.33M -$51.54M $9.88M
Beginning Cash Balance $44.25M $8.36M $35.69M $87.23M $25.80M
Effect of Exchange Rate Changes $0.00 $0.00 $0.00 $0.00 $0.00
Free Cash Flow -$12.82M -$10.81M -$14.38M -$54.54M -$15.64M
Net Other Financing Charges – – – -$86,000.00 –

Discussion

No comments yet — be the first to weigh in on CLYM.

Sign in to join the discussion.

Scroll to Top